Which hematology/oncology patients are high priority for ambulatory clinical pharmacist review? A three-round Delphi survey by the National Comprehensive Cancer Network.

导出 LinkOut

翻译打印收藏纠错

作者： Jennifer P,Booth ^[1] ; Julie M,Kennerly-Shah ^[2] ; Lindsey R,Kelley ^[1] ; Donna,Capozzi ^[3] ; Hillary A,Prescott ^[4] ; Scott A,Soefje ^[5] ; Makala B,Pace ^[6] ; Sally Y,Barbour ^[7] ; Ricky F,Tizon ^[8] ; Sarah,DeVincenzo ^[9] ; Cynthia A,Carnes ^[10] ; Marjorie V,Neidecker ^[2]

作者单位： Department of Pharmacy, The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA. ^[1] The Ohio State University-College of Pharmacy, Columbus, OH, USA. ^[2] Department of Pharmacy, Michigan Medicine, Ann Arbor, MI, USA. ^[3] Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. ^[4] Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA, USA. ^[5] Department of Pharmacy, Mayo Clinic, Rochester, MN, USA. ^[6] Department of Pharmacy, Huntsman Cancer Institute, Salt Lake City, UT, USA. ^[7] Department of Pharmacy, Duke Cancer Institute, Durham, NC, USA. ^[8] Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[9] Department of Pharmacy, National Comprehensive Cancer Network, Plymouth Meeting, PA, USA. ^[10]

关键词 Clinical pharmacy ambulatory oncology patient acuity prioritization

主题词人类(Humans);药剂师(Pharmacists);药物相互作用(Drug Interactions);药学服务(Pharmaceutical Services);多数赞同(Consensus);肿瘤(Neoplasms)

DOI 10.1177/10781552231157660

PMID 36803319

发布时间 2023-11-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交